

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Experimental Medicine

ESPS manuscript NO: 17771

Title: Eribulin for heavily pre-treated metastatic breast cancer patients

Reviewer's code: 00504024

Reviewer's country: China

Science editor: Yue-Li Tian

Date sent for review: 2015-03-25 19:45

Date reviewed: 2015-03-30 06:06

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

Interesting report on eribulin. I hope it is more effective for breast cancer in near future research.
This paper deserves publication.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Experimental Medicine

ESPS manuscript NO: 17771

Title: Eribulin for heavily pre-treated metastatic breast cancer patients

Reviewer's code: 00504351

Reviewer's country: Japan

Science editor: Yue-Li Tian

Date sent for review: 2015-03-25 19:45

Date reviewed: 2015-03-30 09:43

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This manuscript "Eribulin for heavily pre-treated metastatic breast cancer patients" reported a series of patients suffered from metastatic breast cancer with the treatment of eribulin. It arranged some data about eribulin mesylate used in treating those patients, its useful clinical activity and adverse effect profile. It worth to read but the authors should rearrange the manuscript and the figures and tables should be corrected since they are too indistinct. Comments 1. The first paragraph in results segment should be included in patients and methods segment or it will make confusions for readers. 2. In the first paragraph of "results" segment, "ER and/or PR" should give an explaining (PR at segment of "patients and methods" means partial response). 3. Remaking the figures and tables clearly. 4. Add figures legend.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Experimental Medicine

ESPS manuscript NO: 17771

Title: Eribulin for heavily pre-treated metastatic breast cancer patients

Reviewer's code: 00070055

Reviewer's country: Malaysia

Science editor: Yue-Li Tian

Date sent for review: 2015-03-25 19:45

Date reviewed: 2015-03-31 15:36

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The paper described the observed outcomes of Eribulin treatment on a few breast cancer patients, it is a well written paper with a clear information on the outcomes of the treatment. It is a topic of interest to the journal's readers, I recommend this paper for publication in Journal of Experimental Medicine.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Experimental Medicine

ESPS manuscript NO: 17771

Title: Eribulin for heavily pre-treated metastatic breast cancer patients

Reviewer's code: 00503062

Reviewer's country: Japan

Science editor: Yue-Li Tian

Date sent for review: 2015-03-25 19:45

Date reviewed: 2015-03-27 18:46

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input checked="" type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input type="checkbox"/> Minor revision
		BPG Search:	<input checked="" type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The manuscript by Digklia and Voutsadakis showed eribulin treatment outcomes of 21 patients with metastatic breast cancer and found that eribulin has some activity to the patients although their short progression-free survival (PFS) times. The manuscript has some value in that they did find some effect of eribulin treatment in patients with metastatic breast cancer. However, the manuscript has much room to be revised before publication. Especially, the figures and tables are very hard to read and understand. They should be revised. Page 4, line 2 from the bottom: What do ER and PR stand for? Explain them. The PR is different from PR in page 4, line 11 (partial response), isn't it? Titles and legends of figures should be described instead of just "Figure 1 or 2". Letters of Tables and Figures are very difficult to read. The resolutions of letters in Figures and Tables have to be revised.